Extension of Type 2 Diabetes Genome-Wide Association Scan Results in the Diabetes Prevention Program
Authors:
- Robert L. HansonRHRobert L. Hanson
- Alan R. ShuldinerASAlan R. Shuldiner
- David AltshulerDADavid Altshuler
- for the Diabetes Prevention Program Research GroupFGfor the Diabetes Prevention Program Research Group
Open Access
- 1 September 2008
- journal article
- Published by American Diabetes Association in Diabetes
- Vol. 57 (9) , 2503-2510
Abstract
OBJECTIVE— Genome-wide association scans (GWASs) have identified novel diabetes-associated genes. We evaluated how these variants impact diabetes incidence, quantitative glycemic traits, and response to preventive interventions in 3,548 subjects at high risk of type 2 diabetes enrolled in the Diabetes Prevention Program (DPP), which examined the effects of lifestyle intervention, metformin, and troglitazone versus placebo. RESEARCH DESIGN AND METHODS— We genotyped selected single nucleotide polymorphisms (SNPs) in or near diabetes-associated loci, including EXT2, CDKAL1, CDKN2A/B, IGF2BP2, HHEX, LOC387761, and SLC30A8 in DPP participants and performed Cox regression analyses using genotype, intervention, and their interactions as predictors of diabetes incidence. We evaluated their effect on insulin resistance and secretion at 1 year. RESULTS— None of the selected SNPs were associated with increased diabetes incidence in this population. After adjustments for ethnicity, baseline insulin secretion was lower in subjects with the risk genotype at HHEX rs1111875 (P = 0.01); there were no significant differences in baseline insulin sensitivity. Both at baseline and at 1 year, subjects with the risk genotype at LOC387761 had paradoxically increased insulin secretion; adjustment for self-reported ethnicity abolished these differences. In ethnicity-adjusted analyses, we noted a nominal differential improvement in β-cell function for carriers of the protective genotype at CDKN2A/B after 1 year of troglitazone treatment (P = 0.01) and possibly lifestyle modification (P = 0.05). CONCLUSIONS— We were unable to replicate the GWAS findings regarding diabetes risk in the DPP. We did observe genotype associations with differences in baseline insulin secretion at the HHEX locus and a possible pharmacogenetic interaction at CDKNA2/B.Keywords
This publication has 26 references indexed in Scilit:
- Association Analysis in African Americans of European-Derived Type 2 Diabetes Single Nucleotide Polymorphisms From Whole-Genome Association StudiesDiabetes, 2008
- Genetic Susceptibility to Type 2 Diabetes and Implications for Antidiabetic TherapyAnnual Review of Medicine, 2008
- Common Variants of the Novel Type 2 Diabetes GenesCDKAL1andHHEX/IDEAre Associated With Decreased Pancreatic β-Cell FunctionDiabetes, 2007
- Studies of Association of Variants Near the HHEX, CDKN2A/B, and IGF2BP2 Genes With Type 2 Diabetes and Impaired Insulin Release in 10,705 Danish SubjectsDiabetes, 2007
- Polymorphisms within Novel Risk Loci for Type 2 Diabetes Determine β-Cell FunctionPLOS ONE, 2007
- A Genome-Wide Association Study of Type 2 Diabetes in Finns Detects Multiple Susceptibility VariantsScience, 2007
- A genome-wide association study identifies novel risk loci for type 2 diabetesNature, 2007
- Variants in common diseasesNature, 2007
- TCF7L2Polymorphisms and Progression to Diabetes in the Diabetes Prevention ProgramNew England Journal of Medicine, 2006
- The Structure of Haplotype Blocks in the Human GenomeScience, 2002